Milan, Italy

Mattia Marchini

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Italfarmaco Spa. Active years: 2022.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mattia Marchini: Innovator in Selective HDAC6 Inhibitors

Introduction

Mattia Marchini is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective HDAC6 inhibitors. His work focuses on creating novel compounds that exhibit high selective inhibitory activity against the histone deacetylase 6 (HDAC6) enzyme.

Latest Patents

Mattia Marchini holds 1 patent for his invention titled "Selective HDAC6 inhibitors." This patent relates to novel benzohydroxamic compounds of formula (I) and (II), along with their pharmaceutically acceptable salts, isomers, and prodrugs. These compounds are designed to target and inhibit the HDAC6 enzyme, which plays a crucial role in various cellular processes.

Career Highlights

Mattia is currently employed at Italfarmaco Spa, a prominent pharmaceutical company. His role involves research and development, where he applies his expertise to advance innovative therapeutic solutions. His contributions have been instrumental in the company's efforts to enhance drug efficacy and safety.

Collaborations

Some of Mattia's coworkers include Barbara Vergani and Gianluca Caprini. Their collaborative efforts contribute to the dynamic research environment at Italfarmaco Spa, fostering innovation and the development of new therapeutic agents.

Conclusion

Mattia Marchini is a distinguished inventor whose work on selective HDAC6 inhibitors showcases his commitment to advancing pharmaceutical science. His innovative approach and collaboration with talented colleagues position him as a key figure in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…